Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of MK-0616 in Adults With Hypercholesterolemia
2022-502777-42-01Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and atherosclerotic disease comparing MK-0616 with Placebo (2 arms). Primary endpoints: Percent Change from Baseline in LDL-C at Week 24, Number of Participants With One or More Adverse Events and 1 more. Started Jan 2024; status: completed.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemiaatherosclerotic disease
Beyond the preview
Go deeper on 2022-502777-42-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502777-42-01.